Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previously defined osimertinib-resistant EGFR mutations (C797S, C797G, L792H) were the most common resistance mechanism in T790M-preserved cases (11/19).
“In the T790M-preserved group, previously defined osimertinib-resistant EGFR mutations (11/19; C797S: 8; C797G: 1; L792H: 2 [20] [21]) were the most common resistance mechanisms.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC (2018) · cites this paper as [21]
The citation lists haven’t been fetched yet
References 8 · Cited by 89
- Authors
- Chen, K., Zhou, F., Shen, W., Jiang, T., Wu, X., Tong, X., Shao, Y. W., Qin, S., & Zhou, C.
- Affiliations
- First Affiliated Hospital of Soochow University (CN)
- Tongji University (CN)
- Jiangsu University (CN)
- Corresponding author
- Zhou, Caicun
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 12
- Issue
- 6
- Pages
- e65-e68
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2578673768
- Cited by
- 89
- References
- 8
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 12 · 2019: 10 · 2018: 22 · 2017: 11
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR, osimertinib, acquired drug resistance, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, T790M mutation, third-generation TKIs, Chinese patients
- MeSH terms
- Acrylamides, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Lung Neoplasms, Mutation, Piperazines, Prognosis, Pyrimidines, Drug Resistance, Neoplasm, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
